16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list. It...

The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza...

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...

Summit, NJ 30 Jul 2020 Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season Seqirus is...

This news release is intended for medical, pharmaceutical industry and business media Maidenhead, UK 08 Jun 2020 The European Commission has today given regulatory approval for the first...

Oslo, Melbourne and Brisbane 05 Jun 2020 CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate CEPI and CSL will share costs...

GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY −Partnership brings together world-leading plasma companies to focus on developing and...

Safeguarding our people and communities remains our top priority. 03 Apr 2020 As the COVID-19 pandemic evolves, we are continuing to take steps to ensure the health and safety of our workforce and...

This news release is intended for medical and pharmaceutical trade media and financial media only 31 Mar 2020 Seqirus, a global leader in influenza prevention, today announced that its adjuvanted...